For adults with relapsed refractory (r/r) Follicular Lymphoma (FL), a type of non-Hodgkin lymphoma

What is KYMRIAH® (tisagenlecleucel)?

KYMRIAH is an individualized treatment made just for you.


KYMRIAH is a treatment used in adult patients with follicular lymphoma (FL), a type of non-Hodgkin lymphoma, that has relapsed (went into remission, then came back) or is refractory (did not go into remission after receiving other lymphoma treatments) after having at least two other kinds of treatment.

KYMRIAH is a type of immunotherapy called CAR-T cell therapy, or chimeric antigen receptor T cell therapy.

KYMRIAH is made up of your own T cells that have been reprogrammed to recognize the antigen CD19, allowing them to better detect and destroy cancerous (and normal) B cells in the body.

How could KYMRIAH help me?

Traditional therapies (pills, chemo, transplant) for r/r FL may involve indefinite repeated cycles of treatment. KYMRIAH uses your own immune system to potentially fight your cancer with a single infusion—with the goal of breaking the continuous treatment cycle of r/r FL.

How can I get started with KYMRIAH?

If your cancer has returned or not responded after two other kinds of treatment, KYMRIAH may be right for you.


You do not have to be in remission (or get into remission) to begin KYMRIAH therapy.

The first step is to talk to your doctor about KYMRIAH. For help speaking with your doctor, including questions to ask and topics to discuss, download the Doctor Discussion Guide and bring it with you to your appointment.

What side effects may I experience?

Your treatment team is specifically trained to monitor for and manage these potential side effects. Most side effects happen in the weeks following infusion with KYMRIAH.


Call your health care provider or seek emergency help right away if you experience any of the following:


  • Difficulty breathing
  • Fever (100.4°F/38°C or higher)
  • Chills/shaking chills
  • Confusion
  • Severe muscle or joint pain
  • Very low blood pressure
  • Dizziness/lightheadedness
  • Loss of balance
  • Seizures
  • Difficulty speaking and understanding

You may be admitted to the hospital and treated with other medications if you have any of these side effects. If you are admitted to the hospital, tell the health care provider that you have received KYMRIAH.
Because of the risk of cytokine release syndrome and neurological toxicities, KYMRIAH is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the KYMRIAH REMS.

Where can I go for support?

KYMRIAH CARESTM is a support program designed to provide you with dedicated support programs to help you access your KYMRIAH therapy.


Whether you have questions about KYMRIAH, treatment center locations, or insurance coverage, a KYMRIAH CARES case manager is here to help.


To learn more, please call KYMRIAH CARES at (1-844-459-6742) from 8:00 AM to 8:00 PM ET.

Kymriah Cares logo

Patient support icon

Patient Support
Provides access to resources for patients such as financial assistance, patient support programs, information about insurance coverage, and more.

Coordination of care support icon

Coordination of Care Support
Provides help finding a KYMRIAH Treatment Center location.

General Support

Expand all

The organizations and websites listed on this page are maintained by third parties over whom Novartis Pharmaceuticals Corporation has no control. As such, Novartis Pharmaceuticals Corporation makes no representation as to the accuracy or any other aspect of the information supplied by these organizations or contained on these websites. The organizations listed on this page do not specifically endorse the use of KYMRIAH® (tisagenlecleucel).